AI-driven cancer detection platform C the Signs has raised GBP5,000,000 in Series-A funding round led by MMC Ventures.
AI-driven cancer detection platform C the Signs has raised GBP5,000,000 in Series-A funding round led by MMC Ventures.
The investment from MMC, Ataraxia and Acequia Capital, alongside notable Angels including the past CEO of AXA Health, past CEO of Bupa, and Founder of Monzo, will be transformative in driving forward plans to scale the impact of the technology to accelerate early cancer detection and survival.
In 2021, C the Signs conducted over 100,000 patient risk-assessments and diagnosed over 6,000 patients with cancer. The system has been instrumental during the pandemic, detecting more patients with cancer compared to pre-pandemic levels. C the Signs aims to have its technology in the hands of every GP Practice in the UK by the end of 2022.
The C the Signs AI system analyses thousands of data points, using a combination of clinical signs, symptoms, risk factors and other markers, in order to spot which cancer(s) a patient is at risk of and fast-track them to the most appropriate test or referral – in less than 30 seconds.
Founded by two NHS doctors following the loss of a patient due to a delayed cancer diagnosis, Dr Bea Bakshi and Dr Miles Payling set out to transform early cancer detection and build a future where every patient survives cancer.
